contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-secured-a-07-meur-agreement-for-the-italian-moli-sani-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analytiker

Frans-Mikael Rostedt

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Inderes              Sisäpiiritieto: Merkittävä edistysaskel Yhdysvalloissa - Nightingale Healthin...    Nightingale Health Oyj | Sisäpiiritieto | 09.02.2026 klo 21:30:00 EETNightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF), sairastumisriskien tunnistamisen ja ennaltaehkäisevän ...                             Håbentlig kan vi få en analytikers syn på dette, da det i en lægmands ører lyder som en stor sag. ”Efter en retsafgørelse i USA i 2025 forbliver laboratorieudviklede tests (”LDT-tests”) i USA hovedsageligt underlagt CLIA/CLEP-reguleringssystemet og er ikke underlagt den amerikanske fødevare- og lægemiddelstyrelse FDA’s regulering. Nightingale Health er derfor i en god position efter at have fået CLEP-tilladelsen, da der ikke kræves en separat FDA-godkendelse til LDT-tests.”

God start for mit vedkommende, da jeg er nede med omkring 15 % fra entry på ca. tre uger.

ja, med det salgspres vil mange snart lide et ordentligt tab på det her

Grunden er, at den markedspris, aktionærerne har sat på selskabet, stadig er hundrede millioner euro for et selskab med en omsætning på seks millioner og et underskud på næsten tyve millioner. Der er altså stadig masser af plads til fald.

Den ser ud til at være faldet 40 % på tre måneder uden nogen egentlig grund. I den slags aktier ser det ud til, at faldet føder yderligere fald, så trenden knækker nok først, når de kommercielle projekter når helt i mål. Hvis det ikke sker i dette regnskabsår (under 6 måneder tilbage), så sker det aldrig, kunne man formode.

Der er ret lidt købelyst i luften. Der er en risiko for, at den siver ned omkring nettokassen igen, altså til priser et godt stykke under en euro, hvis der ikke kommer nyheder.

Om en uge afholder Sitra et arrangement, hvor dette, der er blevet forberedt i et år, bliver offentliggjort: Terveystiedon tulevaisuus tekoälyn aikakaudella – kansallisen mallin julkistustilaisuus (Fremtidens sundhedsdata i kunstig intelligensens tidsalder – lancering af den nationale model) Sunak er også med i panelet for at dele sine input.                   Sitra              Terveystiedon tulevaisuus tekoälyn aikakaudella – kansallisen mallin...          Est. reading time: 3 minuuttia

Nightingale Health

The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025. 

Translation: Original published in Finnish on 07/07/2025 at 09:03 am EEST
Nightingale <a href="https://www.inderes.se/releases/nightingale-health-selected-as-provider-for-landmark-italian-population-study">was selected</a> as the metabolomics analysis provider for the renowned Moli-sani study in Italy. The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025. The agreement is significant for the company&apos;s research business and supports our growth forecasts for the second half of 2025. The company&apos;s revenue from other European countries (including Italy) was some 0.8 MEUR in 2024, making the agreement a significant size in comparison. This is a project-based revenue item, but we believe the agreement is a good additional reference for Nightingale&apos;s technology.
The Moli-sani study, led by INM Neuromed, investigates risk factors associated with major chronic diseases. With Nightingale Health&#x2019;s advanced technology, the study will now examine the impact of nutritional and environmental factors on health.&#xa0;&#xa0; The study also explores biological signatures associated with healthy aging and aims to identify population subgroups with different responses to preventative interventions. Nightingale was selected for the project in accordance with Italian public procurement law, and the parties are now proceeding to finalize the service agreement.

	2024	25e	26e
Omsætning	4,4	5,2	8,2
vækst-%	4,2 %	19,5 %	57,5 %
EBIT (adj.)	-18,6	-17,3	-16,2
EBIT-% (adj.)	-426,6 %	-331,4 %	-197,6 %
EPS (adj.)	-0,29	-0,27	-0,25
Udbytte	0,00	0,00	0,00
Udbytte %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Nightingale secured a 0.7 MEUR agreement for the Italian Moli-sani study

Key Estimate Figures11.06.2025

Forumopdateringer